Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis

"Pros" and "Cons"

Fulvia Ceccarelli, Cecilia Chighizola, Guido Finazzi, Pier Luigi Meroni, Guido Valesini

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The presence of anti-phospholipid (aPL) is necessary but not sufficient to induce a thrombotic event. The "second hit" hypothesis suggested that an additional trigger may be needed to develop a vascular event in aPL carriers. In this article, pro and con of primary thromboprophylaxis in aPL carriers is deeply discussed, concluding that univocal data are not available, due to conflicting results of available clinical trials. However, in clinical practice the primary thromboprophylaxis is not indicated in all unselected asymptomatic aPL carriers, and the best strategy begin with the assessment of the peculiar risk profile of the subject. Thus, it is mandatory to eliminate modifiable prothrombotic risk factors (i.e. smoking, oral contraceptive), to treat the irreversible risk factors (i.e. hypertension, diabetes) and to introduce an aggressive prophylaxis with subcutaneous LMWH in high-risk situations (i.e. surgical procedures with prolonged immobilization). A different evaluation should be addressed to aPL carriers with a concomitant autoimmune disease that are considered as an additional pro-thrombotic risk factor. Similarly, concomitant positivity for more than one anti-phospholipid test confer a stronger risk of developing the thrombotic manifestations. Specific trials with larger cohorts of patients are needed to better clarify this issue.

Original languageEnglish
Pages (from-to)568-571
Number of pages4
JournalAutoimmunity Reviews
Volume11
Issue number8
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Antiphospholipid Antibodies
Phospholipids
Thrombosis
Low Molecular Weight Heparin
Oral Contraceptives
Immobilization
Autoimmune Diseases
Blood Vessels
Smoking
Clinical Trials
Hypertension

Keywords

  • Anti-phospholipid antibodies
  • Carriers
  • Risk factors
  • Thromboprophylaxis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis : "Pros" and "Cons". / Ceccarelli, Fulvia; Chighizola, Cecilia; Finazzi, Guido; Meroni, Pier Luigi; Valesini, Guido.

In: Autoimmunity Reviews, Vol. 11, No. 8, 06.2012, p. 568-571.

Research output: Contribution to journalArticle

Ceccarelli, Fulvia ; Chighizola, Cecilia ; Finazzi, Guido ; Meroni, Pier Luigi ; Valesini, Guido. / Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis : "Pros" and "Cons". In: Autoimmunity Reviews. 2012 ; Vol. 11, No. 8. pp. 568-571.
@article{056aea9bfaf240c287008c0bddbfce18,
title = "Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: {"}Pros{"} and {"}Cons{"}",
abstract = "The presence of anti-phospholipid (aPL) is necessary but not sufficient to induce a thrombotic event. The {"}second hit{"} hypothesis suggested that an additional trigger may be needed to develop a vascular event in aPL carriers. In this article, pro and con of primary thromboprophylaxis in aPL carriers is deeply discussed, concluding that univocal data are not available, due to conflicting results of available clinical trials. However, in clinical practice the primary thromboprophylaxis is not indicated in all unselected asymptomatic aPL carriers, and the best strategy begin with the assessment of the peculiar risk profile of the subject. Thus, it is mandatory to eliminate modifiable prothrombotic risk factors (i.e. smoking, oral contraceptive), to treat the irreversible risk factors (i.e. hypertension, diabetes) and to introduce an aggressive prophylaxis with subcutaneous LMWH in high-risk situations (i.e. surgical procedures with prolonged immobilization). A different evaluation should be addressed to aPL carriers with a concomitant autoimmune disease that are considered as an additional pro-thrombotic risk factor. Similarly, concomitant positivity for more than one anti-phospholipid test confer a stronger risk of developing the thrombotic manifestations. Specific trials with larger cohorts of patients are needed to better clarify this issue.",
keywords = "Anti-phospholipid antibodies, Carriers, Risk factors, Thromboprophylaxis",
author = "Fulvia Ceccarelli and Cecilia Chighizola and Guido Finazzi and Meroni, {Pier Luigi} and Guido Valesini",
year = "2012",
month = "6",
doi = "10.1016/j.autrev.2011.10.014",
language = "English",
volume = "11",
pages = "568--571",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis

T2 - "Pros" and "Cons"

AU - Ceccarelli, Fulvia

AU - Chighizola, Cecilia

AU - Finazzi, Guido

AU - Meroni, Pier Luigi

AU - Valesini, Guido

PY - 2012/6

Y1 - 2012/6

N2 - The presence of anti-phospholipid (aPL) is necessary but not sufficient to induce a thrombotic event. The "second hit" hypothesis suggested that an additional trigger may be needed to develop a vascular event in aPL carriers. In this article, pro and con of primary thromboprophylaxis in aPL carriers is deeply discussed, concluding that univocal data are not available, due to conflicting results of available clinical trials. However, in clinical practice the primary thromboprophylaxis is not indicated in all unselected asymptomatic aPL carriers, and the best strategy begin with the assessment of the peculiar risk profile of the subject. Thus, it is mandatory to eliminate modifiable prothrombotic risk factors (i.e. smoking, oral contraceptive), to treat the irreversible risk factors (i.e. hypertension, diabetes) and to introduce an aggressive prophylaxis with subcutaneous LMWH in high-risk situations (i.e. surgical procedures with prolonged immobilization). A different evaluation should be addressed to aPL carriers with a concomitant autoimmune disease that are considered as an additional pro-thrombotic risk factor. Similarly, concomitant positivity for more than one anti-phospholipid test confer a stronger risk of developing the thrombotic manifestations. Specific trials with larger cohorts of patients are needed to better clarify this issue.

AB - The presence of anti-phospholipid (aPL) is necessary but not sufficient to induce a thrombotic event. The "second hit" hypothesis suggested that an additional trigger may be needed to develop a vascular event in aPL carriers. In this article, pro and con of primary thromboprophylaxis in aPL carriers is deeply discussed, concluding that univocal data are not available, due to conflicting results of available clinical trials. However, in clinical practice the primary thromboprophylaxis is not indicated in all unselected asymptomatic aPL carriers, and the best strategy begin with the assessment of the peculiar risk profile of the subject. Thus, it is mandatory to eliminate modifiable prothrombotic risk factors (i.e. smoking, oral contraceptive), to treat the irreversible risk factors (i.e. hypertension, diabetes) and to introduce an aggressive prophylaxis with subcutaneous LMWH in high-risk situations (i.e. surgical procedures with prolonged immobilization). A different evaluation should be addressed to aPL carriers with a concomitant autoimmune disease that are considered as an additional pro-thrombotic risk factor. Similarly, concomitant positivity for more than one anti-phospholipid test confer a stronger risk of developing the thrombotic manifestations. Specific trials with larger cohorts of patients are needed to better clarify this issue.

KW - Anti-phospholipid antibodies

KW - Carriers

KW - Risk factors

KW - Thromboprophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84861480764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861480764&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2011.10.014

DO - 10.1016/j.autrev.2011.10.014

M3 - Article

VL - 11

SP - 568

EP - 571

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 8

ER -